دورية أكاديمية
Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome.
| العنوان: | Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome. |
|---|---|
| المؤلفون: | Perla HT; Department of Cardiology, Christian Medical College and Hospital, Vellore, India., Thomson VS; Department of Cardiology, Christian Medical College and Hospital, Vellore, India. vijisamuel1970@gmail.com.; Salalah Heart Center, Salalah, Oman. vijisamuel1970@gmail.com., Attumalil TV; Department of Cardiology, Christian Medical College and Hospital, Vellore, India., Geevar T; Department of Immunohematology and Transfusion Medicine, Christian Medical College and Hospital, Vellore, India., Alex AG; Department of Cardiology, Christian Medical College and Hospital, Vellore, India., Dave RG; Department of Immunohematology and Transfusion Medicine, Christian Medical College and Hospital, Vellore, India., Nair SC; Department of Immunohematology and Transfusion Medicine, Christian Medical College and Hospital, Vellore, India., Gowri SM; Department of Biostatistics, Christian Medical College and Hospital, Vellore, India., Mony PK; Department of Epidemiology and Population Health, St John's National Academy of Health Sciences, Bangalore, India., George P; Department of Cardiology, Christian Medical College and Hospital, Vellore, India., Joseph G; Department of Cardiology, Christian Medical College and Hospital, Vellore, India. |
| المصدر: | American journal of cardiovascular drugs : drugs, devices, and other interventions [Am J Cardiovasc Drugs] 2023 Jul; Vol. 23 (4), pp. 455-466. Date of Electronic Publication: 2023 Jun 23. |
| نوع المنشور: | Randomized Controlled Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100967755 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-187X (Electronic) Linking ISSN: 11753277 NLM ISO Abbreviation: Am J Cardiovasc Drugs Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Auckland : Adis, Springer International Original Publication: Auckland, New Zealand : Adis International, c2001- |
| مواضيع طبية MeSH: | Blood Platelets* , Acute Coronary Syndrome*/drug therapy, Humans ; Ticagrelor/therapeutic use ; Clopidogrel/therapeutic use ; Ticlopidine/pharmacology ; Ticlopidine/therapeutic use ; Adenosine/pharmacology ; Adenosine/therapeutic use ; Platelet Aggregation Inhibitors/adverse effects ; Treatment Outcome ; Purinergic P2Y Receptor Antagonists/pharmacology ; Purinergic P2Y Receptor Antagonists/therapeutic use |
| مستخلص: | Background: Crushed formulations of specific antiplatelet agents produce earlier and stronger platelet inhibition. We studied the platelet inhibitory effect of crushed clopidogrel in patients with acute coronary syndrome (ACS) and its relative efficacy compared with integral clopidogrel, crushed and integral ticagrelor. Objectives: We aimed to compare the platelet inhibitory effect of crushed and integral formulations of clopidogrel and ticagrelor in patients with acute coronary syndrome (ACS). Methods: Overall, 142 patients with suspected ACS were randomly assigned to receive crushed or integral formulations of clopidogrel or ticagrelor. Platelet inhibition at baseline and 1 and 8 h was assessed using the VerifyNow assay. High on-treatment platelet reactivity (HTPR) ≥ 235 P2Y Results: The PRU and percentage inhibition median (interquartile range) at 1 h for the different formulations were as follows: crushed clopidogrel: 196.50 (155.50, 246.50), 9.36 (- 1.79, 25.10); integral clopidogrel: 189.50 (159.00, 214.00), 2.32 (- 2.67, 19.89); crushed ticagrelor: 59.00 (10.00, 96.00), 75.53 (49.12, 95.18); and integral ticagrelor: 126.50 (50.00, 168.00), 40.56 (25.59, 78.69). There was no significant difference in PRU or percentage platelet inhibition between the crushed and integral formulations of clopidogrel (p = 0.990, p = 0.479); both formulations of ticagrelor were superior to the clopidogrel formulations (p < 0.05). On paired comparison, crushed ticagrelor showed robust early inhibition of platelets compared with the integral formulation (p = 0.03). Crushed clopidogrel exhibited the maximal HTPR of 34.3%, but was < 3% for both formulations of ticagrelor. Conclusions: The platelet inhibitory effect of crushed clopidogrel is not superior to integral preparation in patients with ACS. Crushed ticagrelor produced maximal platelet inhibition acutely. HTPR rates in ACS are similar and very low with both formulations of ticagrelor, and maximal with crushed clopidogrel. Clinical Trials Registry of India identifier number CTRI/2020/06/025647. (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.) |
| References: | Tavenier AH, Hermanides RS, Ottervanger JP, Tolsma R, van Beurden A, Slingerland RJ, et al. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(1):4–12. (PMID: 10.1093/ehjcvp/pvaa09532730628) Price MJ, Berger PB, Teirstein PS, Tanguay J-F, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–105. (PMID: 10.1001/jama.2011.29021406646) Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246–51. (PMID: 10.1016/j.jacc.2004.09.06715653023) Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57. (PMID: 10.1056/NEJMoa090432719717846) Michelson AD, Frelinger III AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009;30(14):1753–63. Zafar MU, Farkouh ME, Fuster V, Chesebro JH. Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. J Interv Cardiol. 2009;22(4):385–9. (PMID: 10.1111/j.1540-8183.2009.00475.x19496900) Rollini F, Franchi F, Angiolillo DJ. Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention. EuroIntervention. 2017;12(14):1681–3. (PMID: 10.4244/EIJV12I14A27628216470) Serenelli M, Pavasini R, Vitali F, Tonet E, Bilotta F, Parodi G, et al. Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis. J Thromb Haemost. 2019;17(6):944–50. (PMID: 10.1111/jth.1443430884109) Rollini F, Franchi F, Hu J, Kureti M, Aggarwal N, Durairaj A, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol. 2016;67(17):1994–2004. (PMID: 10.1016/j.jacc.2016.02.04527012781) Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29(8):992–1000. (PMID: 10.1093/eurheartj/ehn04618263931) Collet J-P, Cayla G, Cuisset T, Elhadad S, Rangé G, Vicaut E, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of Aspirin and Clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J. 2011;161(1):5-12.e5. (PMID: 10.1016/j.ahj.2010.09.02921167334) Collet J-P, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100–9. (PMID: 10.1056/NEJMoa120997923121439) Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933–44. (PMID: 10.1093/eurheartj/ehr42222090660) Rao KRK, Lakshmi KR. Design, development, and evaluation of clopidogrel bisulfate floating tablets. Int J Pharm Investig. 2014;4(1):19. (PMID: 10.4103/2230-973X.12773624678458) Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577–85. (PMID: 10.1161/CIRCULATIONAHA.109.91255019923168) Alexopoulos D, Barampoutis N, Gkizas V, Vogiatzi C, Tsigkas G, Koutsogiannis N, et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clin Pharmacokinet. 2016;55(3):359–67. (PMID: 10.1007/s40262-015-0320-026315810) Park D-W, Lee PH, Jang S, Lim H-S, Kang D-Y, Lee CH, et al. Effect of low-dose versus standard-dose ticagrelor and clopidogrel on platelet inhibition in acute coronary syndromes. J Am Coll Cardiol. 2018;71(14):1594–5. (PMID: 10.1016/j.jacc.2018.02.01029622168) Sharma AR, Vohra M, Shukla V, Guddattu V, Razak Uk A, Shetty R, et al. Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases. Life Sci. 2020;15(245): 117364. (PMID: 10.1016/j.lfs.2020.117364) Gairolla J, Ahluwalia J, Khullar M, Kler R, Kishore K, Medhi B, et al. Clopidogrel response in ischemic stroke patients: is polymorphism or gender more important? Results of the CRISP study. J Clin Neurosci. 2020;76:81–6. (PMID: 10.1016/j.jocn.2020.04.03832317191) Pareed SA, Vijayaraghavan G, Kartha C, Manoj M. Antiplatelet drug resistance in Indians. Ann Clin Cardiol. 2020;2(1):36. (PMID: 10.4103/ACCJ.ACCJ_6_20) Thomson VS, John B, Pati PK, George OK, George PV, Jose J. Non-responders to clopidogrel therapy among Indian patients undergoing elective/adhoc angioplasty. Indian Heart J. 2008;60(6):543–7. (PMID: 19276493) Patel S, Arya V, Saraf A, Bhargava M, Agrawal C. Aspirin and clopidogrel resistance in Indian patients with ischemic stroke and its associations with gene polymorphisms: a pilot study. Ann Indian Acad Neurol. 2019;22(2):147. (PMID: 31007424) Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, et al. Randomized assessment of ticagrelor versus Prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5(6):797–804. (PMID: 10.1161/CIRCINTERVENTIONS.112.97232323169985) Tavenier AH, Hermanides RS, Ottervanger JP, Belitser SV, Klungel OH, Appelman Y, et al. Sex differences in platelet reactivity in patients with ST-elevation myocardial infarction: a sub-analysis of the ON-TIME 3 trial. Front Cardiovasc Med. 2021;8: 707814. (PMID: 10.3389/fcvm.2021.70781434671649) Danielak D, Komosa A, Tomczak A, Graczyk-Szuster A, Lesiak M, Glowka F, et al. Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays. Scand J Clin Lab Investig. 2017;77(3):190–8. (PMID: 10.1080/00365513.2017.1286686) Gremmel T, Kopp CW, Eichelberger B, Koppensteiner R, Panzer S. Sex differences of leukocyte–platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis. Atherosclerosis. 2014;237(2):692–5. (PMID: 10.1016/j.atherosclerosis.2014.10.09525463107) Verdoia M, Pergolini P, Nardin M, Rolla R, Negro F, Gioscia R, et al. Gender differences in platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Cardiovasc Revasc Med. 2020;21(9):1144–9. (PMID: 10.1016/j.carrev.2020.02.00732085942) |
| المشرفين على المادة: | GLH0314RVC (Ticagrelor) A74586SNO7 (Clopidogrel) OM90ZUW7M1 (Ticlopidine) K72T3FS567 (Adenosine) 0 (Platelet Aggregation Inhibitors) 0 (Purinergic P2Y Receptor Antagonists) |
| تواريخ الأحداث: | Date Created: 20230623 Date Completed: 20230710 Latest Revision: 20230718 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1007/s40256-023-00591-8 |
| PMID: | 37351814 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1179-187X |
|---|---|
| DOI: | 10.1007/s40256-023-00591-8 |